SG48375A1 - Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a - Google Patents

Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a

Info

Publication number
SG48375A1
SG48375A1 SG1996009183A SG1996009183A SG48375A1 SG 48375 A1 SG48375 A1 SG 48375A1 SG 1996009183 A SG1996009183 A SG 1996009183A SG 1996009183 A SG1996009183 A SG 1996009183A SG 48375 A1 SG48375 A1 SG 48375A1
Authority
SG
Singapore
Prior art keywords
monophosphoryl lipid
vaccines containing
deacylated monophosphoryl
hepatitis vaccines
hepatitis
Prior art date
Application number
SG1996009183A
Other languages
English (en)
Inventor
Clothilde Thiriart
Natalie Marie-J Garcon-Johnson
Pierre Hauser
Pierre Voet
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG48375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of SG48375A1 publication Critical patent/SG48375A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG1996009183A 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a SG48375A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine

Publications (1)

Publication Number Publication Date
SG48375A1 true SG48375A1 (en) 1998-04-17

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996009183A SG48375A1 (en) 1992-03-27 1993-03-24 Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a

Country Status (28)

Country Link
EP (1) EP0633784B2 (fr)
JP (1) JP3470719B2 (fr)
KR (1) KR100270134B1 (fr)
CN (1) CN1072963C (fr)
AP (1) AP570A (fr)
AT (1) ATE146678T1 (fr)
AU (4) AU3751693A (fr)
CA (1) CA2132833C (fr)
CZ (1) CZ283424B6 (fr)
DE (1) DE69306940T3 (fr)
DK (1) DK0633784T4 (fr)
ES (1) ES2098029T5 (fr)
FI (1) FI110843B (fr)
GR (1) GR3022174T3 (fr)
HK (1) HK1003218A1 (fr)
HU (1) HU221253B1 (fr)
IL (1) IL105161A (fr)
MA (1) MA22842A1 (fr)
MY (1) MY111880A (fr)
NO (1) NO309458B1 (fr)
NZ (1) NZ249868A (fr)
RU (1) RU2121849C1 (fr)
SA (1) SA93130573B1 (fr)
SG (1) SG48375A1 (fr)
SI (1) SI9300149B (fr)
SK (1) SK280160B6 (fr)
UA (1) UA44688C2 (fr)
WO (1) WO1993019780A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
WO1994021292A1 (fr) * 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
WO2000023105A2 (fr) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Produits d'addition et vaccins
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
BRPI0515516B1 (pt) 2004-09-22 2017-08-08 Glaxosmithkline Biologicals S.A. Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
AR053833A1 (es) 2005-03-23 2007-05-23 Glaxosmithkline Biolog Sa Composicion inmunogenetica
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP3714900A1 (fr) 2005-11-04 2020-09-30 Seqirus UK Limited Vaccins avec adjuvants dotés d'antigènes non virions préparés à partir de virus de la grippe cultivés dans une culture cellulaire
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
CA2628206A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
TWI465248B (zh) 2005-12-22 2014-12-21 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
CA2646349A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
EP2476434A1 (fr) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Composition immunogène
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP3456348A1 (fr) 2006-09-11 2019-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d' ufs
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
EA200901578A1 (ru) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
AU2008269439B2 (en) 2007-06-27 2013-12-19 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (fr) 2007-12-24 2013-04-24 Novartis AG Dosages pour vaccins adsorbés contre la grippe
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
RU2585227C2 (ru) 2009-07-15 2016-05-27 Новартис Аг Композиции белка f rsv и способы их получения
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012072088A1 (fr) 2010-12-02 2012-06-07 Bionor Immuno As Conception d'échafaudage peptidique
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP2667892B1 (fr) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Régime d'immunisation contre le vrs
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
NZ702146A (en) 2012-06-06 2016-11-25 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
WO2021160887A1 (fr) 2020-02-14 2021-08-19 Immunor As Vaccin contre le coronavirus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
HU220204B (hu) * 1987-11-18 2001-11-28 Chiron Corp. HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet
WO1989012641A1 (fr) * 1988-06-17 1989-12-28 Genelabs Incorporated Agent viral de l'hepatite non-a/non-b transmis par voie enterique
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
CA2065287C (fr) * 1989-09-15 1999-12-21 Tatsuo Miyamura Isolats hvc nouveaux
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0563091A1 (fr) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. VACCINS A BASE DE l'ANTIGENE D'ENVELOPPE DU VIRUS DE L'HEPATITE B

Also Published As

Publication number Publication date
CA2132833C (fr) 2007-03-06
EP0633784B1 (fr) 1996-12-27
JP3470719B2 (ja) 2003-11-25
EP0633784B2 (fr) 2001-10-17
SA93130573B1 (ar) 2004-08-31
ATE146678T1 (de) 1997-01-15
FI110843B (fi) 2003-04-15
NO943571L (no) 1994-11-14
EP0633784A1 (fr) 1995-01-18
AP9300502A0 (en) 1993-04-30
FI944442A0 (fi) 1994-09-26
AU767755B2 (en) 2003-11-20
DK0633784T4 (da) 2001-12-31
DE69306940T3 (de) 2002-09-19
JPH07505372A (ja) 1995-06-15
CZ235594A3 (en) 1995-02-15
IL105161A0 (en) 1993-07-08
NO943571D0 (no) 1994-09-26
SK280160B6 (sk) 1999-09-10
HK1003218A1 (en) 1998-10-16
KR100270134B1 (ko) 2000-10-16
WO1993019780A1 (fr) 1993-10-14
CZ283424B6 (cs) 1998-04-15
MY111880A (en) 2001-02-28
MA22842A1 (fr) 1993-10-01
DE69306940D1 (de) 1997-02-06
CA2132833A1 (fr) 1993-10-14
CN1085805A (zh) 1994-04-27
ES2098029T5 (es) 2002-03-16
HU9402758D0 (en) 1994-12-28
DK0633784T3 (da) 1997-01-20
SK115294A3 (en) 1995-06-07
AU3751693A (en) 1993-11-08
AU3397499A (en) 1999-08-19
AP570A (en) 1996-11-29
SI9300149A (en) 1993-12-31
GR3022174T3 (en) 1997-03-31
SI9300149B (sl) 2003-02-28
CN1072963C (zh) 2001-10-17
HUT69931A (en) 1995-09-28
RU94042386A (ru) 1996-08-20
IL105161A (en) 1998-08-16
RU2121849C1 (ru) 1998-11-20
NO309458B1 (no) 2001-02-05
NZ249868A (en) 1997-03-24
FI944442A (fi) 1994-09-26
AU1000802A (en) 2002-02-21
KR950700757A (ko) 1995-02-20
UA44688C2 (uk) 2002-03-15
ES2098029T3 (es) 1997-04-16
DE69306940T2 (de) 1997-06-26
AU6445796A (en) 1996-11-07
HU221253B1 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
SG48375A1 (en) Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
HK1023499A1 (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
AP9300541A0 (en) Vaccines
AP9300530A0 (en) Vaccines
EP0477889A3 (en) Full color three-dimensional display system
HU9500417D0 (en) Hepatitis a vaccine
KR0123909B1 (en) A three-dimensional display system
GB9101584D0 (en) A display system for pictorial characters
GB9215233D0 (en) Vaccines
GB9201023D0 (en) Vaccines
GB9213559D0 (en) Vaccines
GB9214871D0 (en) Vaccines
ZA93919B (en) Vaccines
GB9226768D0 (en) Vaccines
EP0426847A4 (en) Three-dimensional image display
GB9211081D0 (en) Vaccines
GB9026154D0 (en) A detachable system of advertising
AU120234S (en) A tray or holding/display means
SG99694G (en) Three dimensional display arraratus
GB9221891D0 (en) Vaccines
GB9217635D0 (en) Vaccines
GB9220360D0 (en) Vaccines
GB9226283D0 (en) Vaccines
ZA935281B (en) Vaccines
GB9211318D0 (en) Vaccines